Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying

Edwards Lifesciences Corp

2022-Q1 EPS reported $0.59 revenue$1,341,200,000

Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.
TAVR sales $881M (+11% reported, +14% underlying); global TAVR opportunity seen doubling to $10B by 2028.
Full-year 2022 guidance: sales $5.5-6.0B, adjusted EPS $2.50-$2.65; Q2 sales $1.36-1.44B.
MITRIS RESILIA valve for mitral position received US FDA approval and launched commercially.
Repurchased ~$400M stock in Q1; free cash flow $221M; cash $1.5B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.